ARTICLE | Clinical News

Insulin Degludec regulatory update

January 2, 2012 8:00 AM UTC

Novo Nordisk submitted an NDA in Japan for insulin Degludec to treat Type I and II diabetes. The long-acting insulin analog is under review in the U.S. and the EU for the indication. Novo also said it...